SPYRIDOULA VASILEIOU to Cell- and Tissue-Based Therapy
This is a "connection" page, showing publications SPYRIDOULA VASILEIOU has written about Cell- and Tissue-Based Therapy.
Connection Strength
1.084
-
T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
Score: 0.643
-
Final outcomes from a phase 2 trial of posoleucel in allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024 09 10; 8(17):4740-4750.
Score: 0.206
-
Assessment of the cytolytic potential of a multivirus-targeted T cell therapy using a vital dye-based, flow cytometric assay. Front Immunol. 2023; 14:1299512.
Score: 0.196
-
The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).
Score: 0.039